Key Points
- CEO Marino Garcia sold 122,918 shares on March 12 at an average price of $81.49, a transaction totaling about $10.02 million disclosed in an SEC filing.
- Dianthus closed an upsized underwritten offering that raised roughly $719 million and announced an early Phase‑3 "go" decision, moves that de‑risked the program and sparked a strong stock rally.
- The company remains a pre‑profit, high‑burn biotech, reporting a recent EPS miss with extremely negative margins and a negative ROE, highlighting operational and timing risks despite the new capital.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the company's stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Dianthus Therapeutics Stock Down 3.1%
Dianthus Therapeutics stock opened at $77.86 on Friday. Dianthus Therapeutics, Inc. has a 52-week low of $13.36 and a 52-week high of $88.02. The firm has a market cap of $3.46 billion, a PE ratio of -18.99 and a beta of 1.56. The company's 50 day moving average is $52.53 and its two-hundred day moving average is $42.56.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%.The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. On average, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.
Dianthus Therapeutics News Roundup
Here are the key news stories impacting Dianthus Therapeutics this week:
- Positive Sentiment: Company news: management announced an early Phase‑3 "go" decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
- Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters' option), strengthening the company's cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering...
- Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to "Strong-Buy" at Raymond James Financial
- Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
- Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
- Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
- Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on DNTH. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the stock a "buy" rating in a report on Monday. Oppenheimer boosted their price objective on Dianthus Therapeutics to $145.00 and gave the stock an "outperform" rating in a research report on Monday. Robert W. Baird upped their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday. TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a report on Monday. Finally, Raymond James Financial upgraded shares of Dianthus Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price target for the stock from $63.00 to $123.00 in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $115.33.
Check Out Our Latest Analysis on Dianthus Therapeutics
Institutional Trading of Dianthus Therapeutics
A number of institutional investors have recently bought and sold shares of DNTH. Wellington Management Group LLP boosted its position in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company's stock worth $101,431,000 after acquiring an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. State Street Corp raised its position in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company's stock worth $62,129,000 after acquiring an additional 836,571 shares in the last quarter. Braidwell LP acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $32,859,000. Finally, Polar Capital Holdings Plc purchased a new stake in Dianthus Therapeutics during the third quarter worth approximately $29,434,000. 47.53% of the stock is owned by hedge funds and other institutional investors.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
